Benlysta, also known by its generic name belimumab, is a medication used to treat systemic lupus erythematosus (SLE) and active,
profundity nephritis in adults and children [1][2]. It is a B-lymphocyte stimulator (BLyS)-specific inhibitor [2].
What is Benlysta's mechanism of action?
Benlysta works by binding to soluble BLyS, preventing it from interacting with its receptor on B cells [3]. This blockage leads to a reduction in the survival of B cells, including autoreactive B cells that contribute to SLE [3]. By decreasing these B cells, Benlysta helps to reduce the production of autoantibodies and other factors involved in lupus pathogenesis [3].
How is Benlysta administered?
Benlysta can be administered intravenously (IV) or subcutaneously (SC) [1][4]. The IV formulation is given as an infusion, typically every four weeks after the initial three doses [4]. The SC formulation is administered as an injection, usually every week or every two weeks after the initial loading dose [4].
What conditions does Benlysta treat?
Benlysta is approved for the treatment of adult patients with active, autoantibody-positive SLE who are receiving standard therapy [1]. It is also indicated for adult and pediatric patients (5 years and older) with active lupus nephritis that are receiving standard therapy [1].
When does Benlysta's patent protection expire?
Patent expiry dates can be complex and vary by country and specific patent claims. Information on Benlysta's patent status and potential expiry can be found on resources like DrugPatentWatch.com [5].
Are there other treatments for lupus and lupus nephritis?
Yes, other treatments for lupus and lupus nephritis exist, depending on the severity and specific manifestations of the disease. These can include corticosteroids, immunosuppressants, antimalarials, and other biologic agents [6]. The choice of treatment is individualized based on patient characteristics and disease activity [6].
What are the potential side effects of Benlysta?
Common side effects associated with Benlysta include nausea, diarrhea, fever, rash, and upper respiratory tract infections [1]. Serious side effects can include hypersensitivity reactions, infections (including opportunistic infections and tuberculosis), and depression [1]. Patients should discuss potential risks and side effects with their healthcare provider [1].
What is the cost of Benlysta?
The cost of Benlysta can vary significantly based on factors such as insurance coverage, geographic location, and whether it is administered in a clinic or at home [7]. Patients seeking detailed pricing information should consult their healthcare provider or insurance provider [7].
How does Benlysta compare to other lupus treatments?
Benlysta is a targeted biologic therapy, distinguishing it from broader immunosuppressants or corticosteroids. Its efficacy and safety profile are evaluated in clinical trials against placebo and standard of care [8]. Comparisons with other biologic agents are ongoing as research evolves [8].
What is the role of B-lymphocyte stimulator (BLyS) in lupus?
BLyS is a protein that plays a crucial role in the survival and maturation of B cells [3]. In autoimmune diseases like lupus, elevated levels of BLyS can contribute to the increased number and activity of autoreactive B cells, leading to the production of autoantibodies that attack the body's own tissues [3].
Can biosimilars of Benlysta be developed?
The development and approval of biosimilars depend on patent expiries and regulatory pathways. Once patent protections expire and regulatory requirements are met, biosimilar versions of Benlysta could potentially become available [5].
What clinical trial data supports Benlysta's use?
Benlysta's efficacy and safety have been established through multiple clinical trials, including the BLISS trials for SLE and the BEL1 study for lupus nephritis [2][8]. These studies demonstrated significant improvements in disease activity and nephritis flares in patients treated with Benlysta compared to placebo [2][8].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125214s133,125220s046lbl.pdf
[2] https://www.gene.com/media/press-releases/detail/23910/benlysta-belimumab-receives-expanded-fda-approval-to-treat-acti
[3] https://www.rheumatology.org/Portals/0/Files/Benlysta%20PDF.pdf
[4] https://www.benlysta.com/en/hcp/how-to-administer-benlysta
[5] https://drugpatentwatch.com/
[6] https://www.mayoclinic.org/diseases-conditions/lupus/diagnosis-treatment/drc-20367810
[7] https://www.health.com/condition/autoimmune-diseases/lupus/benlysta-cost
[8] https://www.nejm.org/doi/full/10.1056/NEJMoa1709014